CN106974992A - A kind of composition for increasing bone density and its application - Google Patents
A kind of composition for increasing bone density and its application Download PDFInfo
- Publication number
- CN106974992A CN106974992A CN201710233326.2A CN201710233326A CN106974992A CN 106974992 A CN106974992 A CN 106974992A CN 201710233326 A CN201710233326 A CN 201710233326A CN 106974992 A CN106974992 A CN 106974992A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- concentrate
- safflower
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037182 bone density Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 18
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 9
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 9
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 9
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 244000241257 Cucumis melo Species 0.000 claims abstract description 9
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 claims abstract description 9
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 9
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 9
- 241001148782 Davallia Species 0.000 claims abstract description 9
- 241000123589 Dipsacus Species 0.000 claims abstract description 9
- 239000004863 Frankincense Substances 0.000 claims abstract description 9
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 9
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract description 9
- 229910052802 copper Inorganic materials 0.000 claims abstract description 9
- 239000010949 copper Substances 0.000 claims abstract description 9
- 239000009136 dragon's blood Substances 0.000 claims abstract description 9
- 239000002689 soil Substances 0.000 claims abstract description 9
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 8
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 8
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 7
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 7
- 235000020224 almond Nutrition 0.000 claims abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 6
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 6
- 235000008434 ginseng Nutrition 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- 229920001661 Chitosan Polymers 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 20
- 239000008213 purified water Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 3
- -1 aminohexose Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 4
- 244000241872 Lycium chinense Species 0.000 claims 4
- 235000015468 Lycium chinense Nutrition 0.000 claims 4
- 239000000706 filtrate Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 244000018633 Prunus armeniaca Species 0.000 claims 2
- 235000009827 Prunus armeniaca Nutrition 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 241000219094 Vitaceae Species 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000021021 grapes Nutrition 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 abstract description 25
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000002303 tibia Anatomy 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Chemical class 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical class N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical class [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of composition for increasing bone density and its application; composition includes D-Glucose aldehydic acid, aminohexose, chitosan oligosaccharide, chitosan, taurine amino monose, ginseng, cucumber, frankincense, myrrh, Radix Angelicae Sinensis, safflower, safflower, dragon's blood, peach kernel, muskmelon seed, Soil unit, the rhizome of davallia, the parts by weight of radix cyathulae 30, dipsacus root, pericarpium zanthoxyli, Ligusticum wallichii, native copper, the radix paeoniae rubrathe, almond; the problem of said composition can solve abnormality of bone density, fundamentally can prevent and treat osteoporosis.
Description
Technical field
The present invention relates to technical field of compositions, and application of the composition in medicine and health food is prepared.
Background technology
With the growth at people's age, the microcirculation of human body can worse and worse, and many elderly's winter legs and feet can be very cool, also
Be it has often been said that：People is old, and pin is first old.The circulation of this explanation body is died down, and local blood flow is reduced, the nutriment in blood
Can not the tissue of ample supply in time.Especially because the various nutrition required for the reduction of Blood flow, bone timely can not be obtained
To supplement, osteotrophy is caused to lack.The elderly changes due to endocrine, and bone mineral is largely lost in, and long-time osteotrophy is not
Good, New bone formation (Gegenbaur's cell) effect is reduced, bone information (osteoclast) effect enhancing, forms osteoporosis.
Osteoporosis is a kind of chronic disease process that is complicated, being produced by many factors, is the common of the elderly
Disease, frequently-occurring disease, main clinical manifestation are lumbago, deformity, fracture, Respiratory Disturbances etc., wherein fracture is osteoporosis
One of most common and serious complication of disease, the quality of life of strong influence people.
Developing osteoporosis rate is high, and harmfulness is big, is paid much attention to by global medical field, and the World Health Organization will
It is classified as one of three big diseases of old people.The current people of the whole world about 200,000,000 suffers from osteoporosis, and its incidence of disease leapt to common disease, multiple
The 7th of disease.As aging population becomes clear day by day, especially China can more serious, veteran form in Future population aging
Under the situation that society gradually forms, person in middle and old age multiple degenerative disease-osteoporosis and its complication are used as, it has also become
One social health problem and the concern for enjoying geriatrist, and the great attention of national governments is caused, therefore will
It is set to annual October 20 " international osteoporosis day ".
Osteoporosis is a Complex Diseases, often the result of many factors comprehensive function.Prevent and treat osteoporosis
The problem of disease is one sufficiently complex, it is extremely difficult once osteoporosis occur and correcting again.Modern medicine believes that, osteoporosis
Disease is a kind of systemic metabolic bone disease, is reduced with bone amount, the Microstructure Fracture of bone is characterized, and causing the fragility of bone increases,
Easily fracture.The final purpose of anti-curing osteoporosis is to reduce the generation of fracture, improves the quality of life of the elderly,
We can strive for recapturing bone amount, increase bone strength to reach this purpose by delaying and reducing bone loss.It arranges substantially
Apply including the sufficient calcium of intake, appropriate physical exertion and prevention bone injury, and give different medicines on this basis and do
In advance, it is finally reached the purpose of prevention and treatment fracture.For osteoporosis, at present, the clinical treatment disease is using most
The medicines such as estrogen, calcium agent, activated vitamin D, calcitonin and fluoride, although achieve certain curative effect, but western medicine is treated
Toxicity adverse reaction be generally existing, such as it is long-term to cause mammary gland and endometrium with the estrogen drugs synthesized
Paraplasm, the order use of bis phosphoric acid salt can reduce bone turnover rate, increase bone fragility, and bone can be caused when fluorides are alone
Softening, there is allergy in vitamin D class and calcitonin.
The deficiency existed in the treatment relative to doctor trained in Western medicine, traditional Chinese medicine has the excellent of uniqueness in terms of senile osteoporosis is prevented and treated
Gesture, while it also avoid the serious side reaction of the western medical treatments such as hormone replacement, has made big in terms of clinical experimental study in recent years
Work is measured, there is larger progress.Osteoporosis belongs to " bone withers ", " heumatism " category in traditional Chinese medicine.Traditional Chinese medicine thinks, bone
Matter osteoporosis have close relationship with kidney deficiency, insufficiency of the spleen, blood stasis, and wherein kidney deficiency is this sick Etiological, and " multiple deficiency and stasis " are
The pathological characteristic of osteoporosis.Therefore, osteoporosis should be basic using kidney in prevention and treatment, based on taste, distinguish
Card opinion is controlled, and by invigorating function of kidney and strengthening bone, polishing invigorating the spleen, stagnation resolvation, reaches the purpose of pre- preventing bone rarefaction.Therefore, the present invention is according to the traditional Chinese medical science
To the understanding and modern pharmacology of bone, there is provided a kind of pharmaceutical composition with increase bone density effect.
The content of the invention
Therefore, the technical problems to be solved by the invention be provide it is a kind of have increase bone density effect composition and
Its preparation method.
In order to solve the above technical problems, the invention provides a kind of composition that there is increase bone density to act on, its raw material
Weight is constituted：The parts by weight of cucumber 10-80, the parts by weight of frankincense 2-50, the parts by weight of myrrh 2-50, the weight of Radix Angelicae Sinensis 3-60
Measure part, the parts by weight of safflower 2-30, the parts by weight of safflower 5-50, the parts by weight of dragon's blood 5-50, the parts by weight of peach kernel 3-50, muskmelon seed
10-60 parts by weight, the parts by weight of Soil unit 5-50, the parts by weight of the rhizome of davallia 5-50, radix cyathulae 3--50 parts by weight, the weight of dipsacus root 5-50
Measure part, the parts by weight of pericarpium zanthoxyli 5-50, the parts by weight of Ligusticum wallichii 5-50, the parts by weight of native copper 2-20, the parts by weight of the radix paeoniae rubrathe 5-50, almond
3--50 parts by weight.
It is preferred that, the raw material weight composition of the composition is：50 parts by weight of cucumber, the parts by weight of frankincense 30, system do not have
The parts by weight of medicine 30, the parts by weight of Radix Angelicae Sinensis 30, the parts by weight of safflower 20, the parts by weight of safflower 30, the parts by weight of dragon's blood 30, the weight of peach kernel 30
Part, the parts by weight of muskmelon seed 30, the parts by weight of Soil unit 30, the parts by weight of the rhizome of davallia 30, the parts by weight of radix cyathulae 30, the parts by weight of dipsacus root 30, river
The parts by weight of green pepper 30, the parts by weight of Ligusticum wallichii 30, the parts by weight of native copper 10, the parts by weight of the radix paeoniae rubrathe 30, the parts by weight of almond 40.
The invention provides a kind of preparation method of composition, comprise the following steps：
(1) Radix Angelicae Sinensis, safflower, safflower are weighed according to selected parts by weight, the mass concentration for adding 10 times of drug weights is
75% ethanol is extracted 2 times, each 1.5h, is merged extract solution and is filtered, and is reclaimed ethanol and is concentrated under reduced pressure into relative density at 60 DEG C
1.20 concentrate I, it is standby；
(2) dragon's blood, peach kernel, muskmelon seed, Soil unit, the rhizome of davallia, radix cyathulae are weighed according to selected parts by weight, adds purifying and carry
Take 2 times, add the purified water of 10 times of drug weights to extract 2h for the first time, the purified water of second plus 10 times drug weight extracts 1h,
Merge extract solution simultaneously to filter, be concentrated into the concentrate II of relative density 1.15 at 80 DEG C, it is standby；
(3) weigh cucumber according to selected parts by weight, it is frankincense, myrrh, dipsacus root, pericarpium zanthoxyli, Ligusticum wallichii, native copper, red
Chinese herbaceous peony, almond, add purified water and extract 2 times, add the purified water of 10 times of drug weights to extract 2h, second plus 10 times of medicines for the first time
The purified water of weight extracts 1h, filters, is concentrated under reduced pressure into the concentrate of relative density 1.20 at 60 DEG C, and add 70% ethanol alcohol
It is heavy, take supernatant to reclaim ethanol, gained sediment is concentrated under reduced pressure into the concentrate III of relative density 1.15 at 60 DEG C, it is standby；
(4) merge above-mentioned concentrate I, II and III, dry, obtain extract powder, be then made and clinically may be used according to common process
The formulation of receiving.
Aforementioned pharmaceutical compositions add customary adjuvant, according to common process be made clinically acceptable capsule, tablet,
Granule, mixture, soft extract, pill, electuary, dripping pill, medicinal tea, tincture, vina, beverage, candy or bakery
The invention provides a kind of by above-mentioned pharmaceutical composition addition customary adjuvant, prepared according to common process
Pharmaceutical preparation, health food or food.
Medicine or health food with increase bone density effect are being prepared the invention provides above-mentioned pharmaceutical composition
Purposes and prepare purposes in the medicine, health food or food of anti-curing osteoporosis.
Beneficial effects of the present invention are as follows：
By changing bone microcirculation, the promoting flow of qi and blood increases Blood flow, while providing sufficient nutrition to bone, promotes
Metabolism, improves Bone nutritional condition, improves sclerotin, excludes bone rubbish, repairs the osteocyte of impaired aging, reaches zhuanggu, strong bone, strong
Bone increases the purpose of bone density.Due to the increase of CBF in bone, the various nutriments required for bone have been obtained fully
Supplement, sclerotin is improved after osteotrophy increase.
Brief description of the drawings
The mouse tibia bone density variation diagram of first group of Normal group of Fig. 1.
The mouse tibia bone density variation diagram of second group of excision both sides ovary group of Fig. 2.
The mouse tibia bone density variation diagram of the 3rd group of excision both sides ovary of Fig. 3 and medication group.
Embodiment
1 prepares composition
The need for present invention experiment, 5 groups of experiments have been carried out according to following table data：
2 preparation methods
(1) ginseng, Radix Angelicae Sinensis, safflower, safflower are weighed according to selected parts by weight, the quality for adding 10 times of drug weights is dense
Spend and extracted 2 times for 75% ethanol, each 1.5h merges extract solution and filtered, reclaim ethanol and be concentrated under reduced pressure at 60 DEG C relative
The concentrate I of density 1.20, it is standby；
(2) dragon's blood, peach kernel, muskmelon seed, Soil unit, the rhizome of davallia, radix cyathulae are weighed according to selected parts by weight, adds purifying and carry
Take 2 times, add the purified water of 10 times of drug weights to extract 2h for the first time, the purified water of second plus 10 times drug weight extracts 1h,
Merge extract solution simultaneously to filter, be concentrated into the concentrate II of relative density 1.15 at 80 DEG C, it is standby；
(3) weigh cucumber according to selected parts by weight, it is frankincense, myrrh, dipsacus root, pericarpium zanthoxyli, Ligusticum wallichii, native copper, red
Chinese herbaceous peony, almond, add purified water and extract 2 times, add the purified water of 10 times of drug weights to extract 2h, second plus 10 times of medicines for the first time
The purified water of weight extracts 1h, filters, is concentrated under reduced pressure into the concentrate of relative density 1.20 at 60 DEG C, and add 70% ethanol alcohol
It is heavy, take supernatant to reclaim ethanol, gained sediment is concentrated under reduced pressure into the concentrate III of relative density 1.15 at 60 DEG C, it is standby；
(4) merge above-mentioned concentrate I, II and III, dry, obtain extract powder, D-Glucose aldehydic acid, aminohexose, shell are few
Sugar, chitosan, taurine amino monose, are then made clinically acceptable formulation according to common process.
3 rat bone density contrast experiments
(1) animal
SPF grades of SD rats (buying from Beijing Vital River Experimental Animals Technology Co., Ltd.) 60 (about 28 weeks), body weight
About 280-300g, is randomly divided into 6 groups, every group 10, wherein being divided into Normal group and medication control group in every group.
(2) experimentation
Under equal conditions fed, administration group is administered according to 1.5% (1500mg/kg) of body weight.Per journal
A data are recorded, are fed after completely 90 days, the bone that two sensitive spots of right femur and fl lower end of one group of rat are determined weekly is close
Degree.
(3) bone densitometry
U.S.'s HOLOGIG companies QDR-2000 types dual energy X-ray absorptionmetry (coefficient of variation (CV) ＜ 1.0%) is used under anaesthesia
Whole body bone mineral content and bone density are scanned, and takes right femur and the sensitive spot of fl lower end two respectively, femur midpoint is measured
With the bone density (BMD) of distal end.
(4) experimental data is counted
All data are represented using mean ± standard deviation (X ± SD), are analyzed, compared between group with SPSS statistical softwares
With variance analysis, significant difference is examined with q.
(5) result
Left and right side femoral bmd index is apparently higher than control group, and difference has conspicuousness and very significant meaning.
4 ovariectomy mouse are tested
(1) animal
SPF grades of SD Female Rats (buying from Beijing Vital River Experimental Animals Technology Co., Ltd.) 60 (about 16 weeks), body
200g is weighed about, is divided into three groups, first group of operation only cuts off fat, the both sides ovary of second group of excision mouse, the 3rd group of excision mouse
Both sides ovary.
(2) same food is fed, the 3rd group of addition composite preparation, is added according to 1.5% (1500mg/kg) of body weight.
(3) after feeding 12 weeks, mouse tibia bone density is determined：
The mouse tibia bone density change of first group of Normal group is not obvious, slightly reduces, such as Fig. 1；
The mouse tibia bone density change of second group of excision both sides ovary group is obvious, hence it is evident that reduction, such as Fig. 2；
The mouse tibia bone density change of 3rd group of excision both sides ovary and medication group is not obvious, hence it is evident that improve, such as Fig. 3.
5 clinical Observation on Bone Mineral Density
(1) samples selection
Criteria of Osteoporosis is used compared with the bone density peak value of local male, is reduced more than 2 standard deviations (SD)
For osteoporosis.According to Chinese Adult lumbar spine bmd value, male's peak value was 1.210 ± 0.102g/cm2, at 50~60 years old
Age bracket, standard deviation is 0.102, therefore is that osteoporosis is suffered from less than this value using 0.790g/cm2 as Criteria of Osteoporosis
Person.
Between case selection in October, -2013 in March, 2013, primary osteoporosis male volunteers 30 are diagnosed as,
It is age 61-73 Sui, average 65.2 years old.Treatment group 15, control group 15 are randomly divided into, two groups of ordinary circumstances compare without substantially poor
It is different.
(2) instructions of taking
Human oral dosage form is 3g compositions, is taken in the morning and evening, dosage period six months.
(3) process is observed
Two groups of bone density numerical value is measured, administration group bone density averagely improves 12.06%, and control group bone density have dropped
4.58%, there is the raising bone density effect of highly significant.
| Group | Number | BMD (%) before administration | BMD (%) after six months | BMD rates of change (%) |
| Administration group | 15 | 72.42±11.32 | 81.15±11.54 | +12.06±5.31 |
| Control group | 15 | 75.22±11.82 | 71.77±11.66 | -4.58±4.13 |
6 samples are tracked
(1)、ID000427004
| Age | 72 |
| Sex | Female |
| Height | 156cm |
| Body weight | 49kg |
| First time time of measuring | 2011-11-10 |
| First time BMD (g/cm2) | 0.4825 |
| Time of measuring after medication | 2012-1-12 |
| BMD (g/cm after medication2) | 0.5032 |
(2)、ID02861769
(3)、ID700242064
| Birthdate | 1945-1-27 |
| Age | 66 |
| Sex | Female |
| Height | 155cm |
| Body weight | 50kg |
| First time time of measuring | 2011-12-19 |
| First time BMD (g/cm2) | 0.431 |
| Time of measuring after medication | 2012-2-6 |
| BMD (g/cm after medication2) | 0.530 |
(4)、ID50767298
| Birthdate | 1953-6-9 |
| Age | 58 |
| Sex | Female |
| Height | 163cm |
| Body weight | 60kg |
| First time time of measuring | 2012-1-4 |
| First time BMD (g/cm2) | 0.806 |
| Time of measuring after medication | 2012-2-8 |
| BMD (g/cm after medication2) | 0.817 |
(5)、ID62982
| Birthdate | 1955-3-15 |
| Age | 56 |
| Sex | Female |
| Height | 163cm |
| Body weight | 60kg |
| First time time of measuring | 2011-11-10 |
| First time BMD (g/cm2) | 0.822 |
| Time of measuring after medication | 2011-12-12 |
| BMD (g/cm after medication2) | 0.844 |
(6)、ID18137
| Birthdate | |
| Age | 67 |
| Sex | Female |
| Height | 176cm |
| Body weight | 110kg |
| First time time of measuring | 2011-1-12 |
| First time BMD (g/cm2) | 1.014 |
| Time of measuring after medication | 2011-12-26 |
| BMD (g/cm after medication2) | 1.029 |
(7)、ID398748
(8)、ID26921
| Birthdate | 1953-3-19 |
| Age | 58 |
| Sex | Female |
| Height | 159cm |
| Body weight | 70kg |
| First time time of measuring | 2011-11-10 |
| First time BMD (g/cm2) | 0.811 |
| Time of measuring after medication | 2012-1-17 |
| BMD (g/cm after medication2) | 0.824 |
(9)、ID20105
| Birthdate | 1953-3-19 |
| Age | 58 |
| Sex | Female |
| Height | 159cm |
| Body weight | 71kg |
| First time time of measuring | 2011-11-10 |
| First time BMD (g/cm2) | 0.778 |
| Time of measuring after medication | 2012-2-2 |
| BMD (g/cm after medication2) | 0.824 |
(10)、ID398748
Claims (7)
1. a kind of increase the composition of bone density, it is characterised in that its raw material weight, which is constituted, is：
The parts by weight of D-Glucose aldehydic acid 5-30, the parts by weight of aminohexose 5-35, the parts by weight of chitosan oligosaccharide 5-50, chitosan 5-
40 parts by weight, ginseng 5-20 amount part, the parts by weight of taurine amino monose 5-50, the parts by weight of cucumber 10-80, frankincense 2-
50 parts by weight, the parts by weight of myrrh 2-50, the parts by weight of Radix Angelicae Sinensis 3-60, the parts by weight of safflower 2-30, the parts by weight of safflower 5-50,
The parts by weight of dragon's blood 5-50, the parts by weight of peach kernel 3-50, the parts by weight of muskmelon seed 10-60, the parts by weight of Soil unit 5-50, the rhizome of davallia 5-
50 parts by weight, 10-50 parts of the root bark of Chinese wolf-berry, radix cyathulae 3--50 parts by weight, the parts by weight of dipsacus root 5-50, the parts by weight of pericarpium zanthoxyli 5-50, river
The parts by weight of rhizome of chuanxiong 5-50, the parts by weight of native copper 2-20, the parts by weight of the radix paeoniae rubrathe 5-50, almond 3--50 parts by weight.
2. composition according to claim 1, it is characterised in that the raw material weight of the composition, which is constituted, is：D- grapes
The parts by weight of uronic acid 20, the parts by weight of aminohexose 20, the parts by weight of chitosan oligosaccharide 20, the parts by weight of chitosan 20, taurine amino monose
Sub 50 parts by weight of 20 parts by weight, the parts by weight of ginseng 10, cucumber, the parts by weight of frankincense 30, the parts by weight of myrrh 30, the weight of Radix Angelicae Sinensis 30
Part, the parts by weight of safflower 20, the parts by weight of safflower 30, the parts by weight of dragon's blood 30, the parts by weight of peach kernel 30, the parts by weight of muskmelon seed 30, Soil unit
30 parts by weight, the parts by weight of the rhizome of davallia 30, the parts by weight of the root bark of Chinese wolf-berry 30, the parts by weight of radix cyathulae 30, the parts by weight of dipsacus root 30, the weight of pericarpium zanthoxyli 30
Part, the parts by weight of Ligusticum wallichii 30, the parts by weight of native copper 10, the parts by weight of the radix paeoniae rubrathe 30, the parts by weight of almond 40.
3. a kind of method for preparing composition described in claim 1 or 2, it is characterised in that comprise the following steps：
(1) ginseng, Radix Angelicae Sinensis, safflower, safflower are weighed according to selected parts by weight, the mass concentration for adding 10 times of drug weights is
50-80% ethanol is extracted 1-3 times, each 1-3h, is merged and filtering gained extract solution, is reclaimed ethanol, then subtract gained filtrate
Pressure is concentrated into the concentrate I of relative density 1.15-1.25 at 60 DEG C, standby；
(2) dragon's blood, peach kernel, muskmelon seed, Soil unit, the rhizome of davallia, the root bark of Chinese wolf-berry, radix cyathulae are weighed according to selected parts by weight, adds 10
The purified water of times drug weight is extracted 1-3 time, each 1-3 hour, is merged and extract solution obtained by filtering, is then subtracted gained filtrate
Pressure is concentrated into the concentrate II of relative density 1.10-1.20 at 80 DEG C, standby；
(3) cucumber, frankincense, myrrh, dipsacus root, pericarpium zanthoxyli, Ligusticum wallichii, native copper, the radix paeoniae rubrathe, apricot are claimed according to selected parts by weight
Benevolence, the purified water for adding 10 times of drug weights is extracted 1-3 times, each 1-3 hours, is merged and filtering gained extract solution, by gained
Filtrate decompression is concentrated into the concentrate of relative density 1.15-1.25 at 60 DEG C, and adds 50-80% ethanol alcohol precipitations, takes supernatant
Ethanol is reclaimed, the concentrate III of relative density 1.10-1.20 at 60 DEG C is concentrated under reduced pressure into, it is standby；
(4) merge above-mentioned concentrate I, II and III, dry, obtain extract powder, add D-Glucose aldehydic acid, aminohexose, shell few
Clinically acceptable formulation is made in sugar, chitosan, taurine amino monose, common process.
4. preparation method according to claim 3, it is characterised in that comprise the following steps：
(1) ginseng, Radix Angelicae Sinensis, safflower, safflower are weighed according to selected parts by weight, the mass concentration for adding 10 times of drug weights is
75% ethanol is extracted 2 times, each 1.5h, is merged extract solution and is filtered, and is reclaimed ethanol and is concentrated under reduced pressure into relative density at 60 DEG C
1.20 concentrate I, it is standby；
(2) dragon's blood, peach kernel, muskmelon seed, Soil unit, the rhizome of davallia, the root bark of Chinese wolf-berry, radix cyathulae are weighed according to selected parts by weight, added pure
Change and extract 2 times, add the purified water of 10 times of drug weights to extract 2h for the first time, the purified water of second plus 10 times drug weight is extracted
1h, merges extract solution and simultaneously filters, and is concentrated into the concentrate II of relative density 1.15 at 80 DEG C, standby；
(3) cucumber, frankincense, myrrh, dipsacus root, pericarpium zanthoxyli, Ligusticum wallichii, native copper, the radix paeoniae rubrathe, apricot are weighed according to selected parts by weight
Benevolence, adds purified water and extracts 2 times, adds the purified water of 10 times of drug weights to extract 2h, second plus 10 times of drug weights for the first time
Purified water extract 1h, filter, be concentrated under reduced pressure into the concentrate of relative density 1.20 at 60 DEG C, and add 70% ethanol alcohol precipitation,
Take supernatant to reclaim ethanol, gained sediment is concentrated under reduced pressure into the concentrate III of relative density 1.15 at 60 DEG C, it is standby；
(4) merge above-mentioned concentrate I, II and III, dry, obtain extract powder, D-Glucose aldehydic acid, aminohexose, chitosan oligosaccharide, shell
Glycan, taurine amino monose, are then made clinically acceptable formulation according to common process.
5. application of the composition in the medicine with increase bone density effect is prepared described in claim 1 or 2.
6. application of the composition in the health food with increase bone density effect is prepared described in claim 1 or 2.
7. application of the composition in the food with increase bone density effect is prepared described in claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710233326.2A CN106974992A (en) | 2017-04-11 | 2017-04-11 | A kind of composition for increasing bone density and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710233326.2A CN106974992A (en) | 2017-04-11 | 2017-04-11 | A kind of composition for increasing bone density and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106974992A true CN106974992A (en) | 2017-07-25 |
Family
ID=59345305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710233326.2A Pending CN106974992A (en) | 2017-04-11 | 2017-04-11 | A kind of composition for increasing bone density and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106974992A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472713A (en) * | 2020-12-03 | 2021-03-12 | 爱希（北京）国际咨询有限公司 | Composition for preventing and treating osteoporosis and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134286A (en) * | 1995-04-28 | 1996-10-30 | 冯文光 | Zhuangguning-medicine for bone fracture |
| JP2008169168A (en) * | 2007-01-15 | 2008-07-24 | Masahiro Wada | Bone density increasing agent |
| CN101618133A (en) * | 2008-06-30 | 2010-01-06 | 广州白云山和记黄埔中药有限公司 | Application of yang-reinforcing kidney-protecting medicine in preparing medicine preventing and treating osteoporosis |
| CN103355660A (en) * | 2012-04-11 | 2013-10-23 | 北京红墙生物工程有限公司 | Healthcare food for improving bone quality and enhancing bone mineral density and preparation method thereof |
| CN104127861A (en) * | 2014-07-31 | 2014-11-05 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition with bone mineral density increasing function and preparation method thereof |
-
2017
- 2017-04-11 CN CN201710233326.2A patent/CN106974992A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134286A (en) * | 1995-04-28 | 1996-10-30 | 冯文光 | Zhuangguning-medicine for bone fracture |
| JP2008169168A (en) * | 2007-01-15 | 2008-07-24 | Masahiro Wada | Bone density increasing agent |
| CN101618133A (en) * | 2008-06-30 | 2010-01-06 | 广州白云山和记黄埔中药有限公司 | Application of yang-reinforcing kidney-protecting medicine in preparing medicine preventing and treating osteoporosis |
| CN103355660A (en) * | 2012-04-11 | 2013-10-23 | 北京红墙生物工程有限公司 | Healthcare food for improving bone quality and enhancing bone mineral density and preparation method thereof |
| CN104127861A (en) * | 2014-07-31 | 2014-11-05 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition with bone mineral density increasing function and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 林飞等: "《保健食品安全性实验方法实用操作手册》", 30 September 2015, 河北科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472713A (en) * | 2020-12-03 | 2021-03-12 | 爱希（北京）国际咨询有限公司 | Composition for preventing and treating osteoporosis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547555B (en) | Chinese medicine composition with effect of nourishing Yin and invigorating kidney and its preparation method and application | |
| CN102670994A (en) | Composition capable of relieving physical fatigue and preparation method of composition | |
| CN104873624A (en) | Pharmaceutical composition for treating gouty arthritis | |
| CN101966222A (en) | Medicinal composition and preparation for strengthening bones and preparation method thereof | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| US9855308B2 (en) | Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same | |
| CN104127861B (en) | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof | |
| CN104352821A (en) | Traditional Chinese medicine granule for treating hypertension | |
| CN104257762B (en) | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of | |
| CN103610795B (en) | A kind of preparation method of eucommia bark depressor oral formulations | |
| CN104352921B (en) | Chinese medicine composition with increase bone density effect and its preparation method and application | |
| CN106974992A (en) | A kind of composition for increasing bone density and its application | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN101708231A (en) | Blood pressure and blood fat reducing oral liquid used for improving sleep quality and preparation method thereof | |
| US20240307458A1 (en) | Medicine composition for treatment of bone and joint diseases originated from medicinal materials and the process for producing thereof | |
| CN100493556C (en) | A drug for treating depressive mood disorder | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN102599501B (en) | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver | |
| CN106511549A (en) | Traditional Chinese medicine composition containing millettia specisoa and preparation method of traditional Chinese medicine composition | |
| CN101375962B (en) | Formulation for activating blood and freeing collateral vessels and preparation method thereof | |
| CN105381154A (en) | Pharmaceutical composition containing moringa oleifera and preparation method of preparation of pharmaceutical composition | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN106138960B (en) | Medical composition and its use | |
| CN103798475B (en) | Chinese herbal medicine honey tea (sugar-free particles) for improving sub-health status of perimenopause and preparation technology thereof | |
| CN104161936B (en) | A kind of Chinese medicine composition of prevention and treatment postmenopausal osteoporosiss and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170725 |
|
| WD01 | Invention patent application deemed withdrawn after publication |